Alto Neuroscience (NYSE:ANRO) Given New $10.00 Price Target at Stifel Nicolaus

Alto Neuroscience (NYSE:ANRO) had its price target trimmed by Stifel Nicolaus from $32.00 to $10.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the company. RODMAN&RENSHAW downgraded Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Wedbush downgraded Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $4.53 on Wednesday. The company’s fifty day simple moving average is $10.20 and its 200-day simple moving average is $11.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. Alto Neuroscience has a 52 week low of $3.61 and a 52 week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05. On average, equities research analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. acquired a new stake in Alto Neuroscience in the 1st quarter valued at approximately $21,267,000. Price T Rowe Associates Inc. MD acquired a new position in Alto Neuroscience in the first quarter worth $9,788,000. Vanguard Group Inc. acquired a new position in shares of Alto Neuroscience during the first quarter worth approximately $8,233,000. Jennison Associates LLC lifted its stake in shares of Alto Neuroscience by 80.3% during the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after acquiring an additional 370,612 shares during the period. Finally, Artal Group S.A. bought a new stake in shares of Alto Neuroscience during the first quarter worth approximately $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.